REPRIEVE final results: What does it mean for guidelines in low‐ and middle‐income countries?

Abstract Introduction The REPRIEVE study demonstrated significant reductions in major adverse cardiovascular events (MACE) with pitavastatin among people living with HIV (PWH) with low to moderate cardiovascular risk. Most MACE events occurred in higher‐income countries, raising important considerat...

Full description

Bibliographic Details

Published in:	Journal of the International AIDS Society
Main Authors:	Simiso Sokhela, Jennifer M. Manne‐Goehler, Samanta Lalla‐Edward, Mark J. Siedner, Mohammed K. Ali, Andrew Hill, Aaloke Mody, Anton Pozniak, Jeremy Nel, W. D. Francois Venter
Format:	Article
Language:	English
Published:	Wiley 2025-06-01
Subjects:	cardiovascular HIV MACE pitavastatin REPRIEVE statin
Online Access:	https://doi.org/10.1002/jia2.26525